Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN

Swedish Orphan Biovitrum AB New York Sweden

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan, including: View original content:https://www.prnewswire.co.uk/news-releases/pivotal-valiant-results-presented-at-kidney-week-show-pegcetacoplan-treatment-effect-in-patients-with-c3g--primary-ic-mpgn-302288008.html